The $293 Million Gold Rush Wall Street Missed

Keith Kohl

Written By Keith Kohl

Posted April 13, 2026

The world is still on fire. 

But were you distracted enough by the geopolitical chaos to miss the Department of Energy dropping a bombshell a few weeks ago?

The DOE is officially shelling out $293.76 million for AI-driven research projects.

This is happening — Now!

And the current deadline is April 28, 2026.

But this isn’t some bureaucratic grant program buried in a 200-page PDF. 

I’m referring to the Genesis Mission  — Trump’s AI Manhattan Project — that’s putting some real money on the table. 

The executive order came down last November, and the message was clear:

Double U.S. research and development productivity within a decade using AI.

Still, Wall Street barely blinked.eac 4-10-26

Everyone has been mesmerized by Nvidia’s $500 billion backlog and Microsoft’s Azure AI dominance, or AWS committing $50 billion to AI and supercomputing expansion. 

So, it’s the usual suspects getting the attention.

Meanwhile, the Department of Energy just handed us a roadmap to pure profit. 

It included more than 26 national science and technology challenges, 51 consortium partners, and explicit funding with hard deadlines. 

A few infrastructure targets can be found at Argonne and Oak Ridge National Laboratories — 10,000-GPU clusters operational by the end of 2026, and a 100,000-GPU monster boost scheduled for 2027.

But here’s the catch… 

What President Trump’s Genesis Mission actually needs is relatively simple. 

We’re talking about biotech platforms with proprietary datasets massive enough to train foundation models on cellular biology, and domestic sources of critical minerals — antimony, lithium, rare earths — because you can’t build supercomputers without the raw materials. 

Of course, we won’t forget the small modular nuclear reactors that provides power 24/7 — the massive power draw AI data centers will need that renewables can’t deliver, or the coming integration of quantum computing. 

You might be surprised where we end up… because it won’t be buying overvalued shares of Big Tech. 

The Genesis Countdown

The DOE Under Secretary Darío Gil put it bluntly recently:

“These challenges represent a bold step toward a future where science moves at the speed of imagination because of AI.”

That’s why the Genesis Mission targets six strategic industries: biotechnology, critical materials, nuclear energy, quantum computing, semiconductors, and advanced manufacturing. 

And you can bet the clock is ticking down quicker than most think — a 270-day deadline that started the moment the executive order was given. 

That’s August 21, 2026. 

That’s how much time the DOE has to demonstrate initial operating capability of the AI platform for at least one national challenge.

The government isn’t looking for approval anymore, and they’re hungry to deploy a lot of capital. 

The Genesis Mission scales that playbook across six industries simultaneously.

For sure, the big three tech plays will benefit (don’t they always?). 

Nvidia’s providing the Blackwell chips powering the Argonne cluster, Microsoft’s Azure already has a $30 billion deal with Anthropic, and AWS is building out supercomputing capacity at a scale that would’ve been unthinkable five years ago.

Make no mistake, these companies will print money…. but everyone already knows that!

The market is still pricing Big Tech at nosebleed valuations, because the Genesis Consortium reveals the execution partners. 

But then you see the specialized plays.

You see, the Genesis Mission’s 26 challenges aren’t generic “use AI to solve cancer” gambles. 

These are very specific, whether it’s the AI-Fusion Digital Convergence Platform to experiment with fusion reactors, digitizing eight decades of U.S. nuclear data into searchable datasets, AI-driven autonomous laboratories, discovering quantum algorithms, or scaling the biotech revolution. 

Each challenge requires different players that can provide the infrastructure, datasets, and expertise. 

After all, the DOE isn’t trying to fund R&D from scratch, but rather accelerate what’s already operational.

That’s why the $293 million Genesis Mission funding — and the much larger capital deployment coming behind it — is flowing to a smaller set of power players. 

I’d even bet most of the herd has never heard of them, because they’re the specialized execution partners building the biotech platforms, mining the critical minerals, deploying the nuclear reactors, and integrating the quantum computing capabilities that Genesis Mission requires.

These are the hidden investment gems buried in the Genesis Mission.

They’re the stocks actually executing, and the ones that’ll reprice once the herd realizes that federal backing just transformed their risk-return profiles completely.

Look, the application deadline has already passed, and we’re quickly moving-on to the next stage — the one where infrastructure’s being built and new partners revealed. 

Wall Street’s still watching Nvidia, but our profit roadmap is hiding in plain sight.

Until next time,

Keith Kohl Signature

Keith Kohl

follow basicCheck us out on YouTube!

A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.

For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.

Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.

Angel Publishing Investor Club Discord - Chat Now

Even Amazon is Investing in Nuclear

Amazon, the global e-commerce powerhouse, is gearing up for a groundbreaking energy revolution. Teaming up with three leading nuclear company, they're making waves with an innovative plan to utilize nuclear energy using Small Nuclear Reactors (SMRs) . The e-commerce giant signed three deals for SMR development in Virginia. We reveal the names and ticker symbol of the company they're partnering with in our FREE report, "Even Amazon Is Investing in Nuclear." This news could make their share price sky rocket at any moment! Sign up below to get your free copy delivered to your inbox right away.

Sign up to receive your free report. After signing up, you'll begin receiving the Energy and Capital e-letter daily.